The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis

International Journal of Cancer

Volumn 133, Issue 4, 2013, Pages 779-787

  Ford, Caroline E ^a   Qian Ma, Sean Si ^a   Quadir, Ashfaque ^a   Ward, Robyn L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

catenin; cancer; metastasis; ROR2; Wnt signaling; Wnt5a

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BETA CATENIN; FRIZZLED PROTEIN; MESSENGER RNA; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; WNT11 PROTEIN; WNT5A PROTEIN;

BRACHYDACTYLY; BREAST CANCER; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOGENESIS; COLORECTAL CANCER; DRUG TARGETING; FRAMESHIFT MUTATION; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CANCER; MELANOMA; METASTASIS POTENTIAL; MISSENSE MUTATION; NONHUMAN; NONSENSE MUTATION; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REVIEW; ROBINOW SYNDROME; SARCOMA; WNT SIGNALING PATHWAY;

CELL TRANSFORMATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84878881838     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27984     Document Type: Review

References (65)

1. Chien AJ, Conrad WH, Moon RT,. A Wnt survival guide: from flies to human disease. J Invest Dermatol 2009; 129: 1614-27.
2. Ying Y, Tao Q,. Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics 2009; 4: 307-12.
3. Torres MA, Yang-Snyder JA, Purcell SM, et al. Activities of the Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant negative cadherin in early Xenopus development. J Cell Biol 1996; 133: 1123-37. (Pubitemid 26172516)
4. Li J, Ying J, Fan Y, et al. WNT5A antagonizes WNT/beta-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer Biol Ther 2010; 10: 617-24.
5. Safholm A, Leandersson K, Dejmek J, et al. A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. J Biol Chem 2006; 281: 2740-9. (Pubitemid 43845737)
6. He X, Saint-Jeannet JP, Wang Y, et al. A member of the Frizzled protein family mediating axis induction by Wnt-5A. Science 1997; 275: 1652-4. (Pubitemid 27120542)
7. Mikels AJ, Nusse R,. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 2006; 4: e115.
8. Tu X, Joeng KS, Nakayama KI, et al. Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Developmental Cell 2007; 12: 113-27. (Pubitemid 46002598)
9. Angers S, Moon RT,. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009; 10: 468-77.
10. van Amerongen R, Mikels A, Nusse R,. Alternative wnt signaling is initiated by distinct receptors. Sci Signal 2008; 1: re9.
11. Masiakowski P, Carroll RD,. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem 1992; 267: 26181-90. (Pubitemid 23014033)
12. Forrester WC, Dell M, Perens E, et al. A C-elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division. Nature 1999; 400: 881-85. (Pubitemid 29406725)
13. Hikasa H, Shibata M, Hiratani I, et al. The Xenopus receptor tyrosine kinase Xror2 modulates morphogenetic movements of the axial mesoderm and neuroectoderm via Wnt signaling. Development 2002; 129: 5227-39. (Pubitemid 35460686)
14. Oishi I, Suzuki H, Onishi N, et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes to Cells 2003; 8: 645-54. (Pubitemid 36880848)
15. Forrester WC,. The Ror receptor tyrosine kinase family. Cell Mol Life Sci 2002; 59: 83-96. (Pubitemid 34117358)
16. Katoh M, Katoh M,. Comparative genomics on ROR1 and ROR2 orthologs. Oncol Rep 2005; 14: 1381-84.
17. Schwabe GC, Trepczik B, Suring K, et al. Ror2 knockout mouse as a model for the developmental pathology of autosomal recessive Robinow syndrome. Dev Dyn 2004; 229: 400-10. (Pubitemid 38140480)
18. Zhang S, Chen L, Cui B, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. Plos One 2012; 7: e31127.
19. Baskar S, Kwong K, Hofer T, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008; 14: 396-404. (Pubitemid 351226106)
20. Morioka K, Tanikawa C, Ochi K, et al. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci 2009; 100: 1227-33.
21. O'Connell MP, Fiori JL, Xu M, et al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 2010; 29: 34-44.
22. Baskar S, Kwong KY, Hofer T, et al. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a potential target antigen for immunotherapy of human B cell chronic lymphocytic leukemia. J Immunother 2006; 29: 671.
23. Shabani M, Asgarian-Omran H, Vossough P, et al. Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leuk Lymphoma 2008; 49: 1360-67. (Pubitemid 352015800)
24. Shabani M, Asgarian Omran H, Jeddi-Tehrani M, et al. Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in iranian patients with acute lymphoblastic leukemia. Tumor Biol 2007; 28: 318-26. (Pubitemid 351567549)
25. Baskar S, Kwong KY, Hofer T, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008; 14: 396-404. (Pubitemid 351226106)
26. DaneshManesh AH, Mikaelsson E, Jeddi-Tehrani M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 2008; 123: 1190-95.
27. Gentile A, Lazzari L, Benvenuti S, et al. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res 2011; 71: 3132.
28. Barna G, Mihalik R, Timár B, et al. ROR1 expression is not a unique marker of CLL. Hematol Oncol 2011; 29: 17-21.
29. Uhrmacher S, Schmidt C, Erdfelder F, et al. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL). Leuk Res 2011; 35: 1360-6.
30. Yang J, Baskar S, Kwong KY, et al. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One 2011; 6: e21018.
31. Daneshmanesh A, Hojjat-Farsangi M, Khan A, et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia 2012; 26: 1348-55.
32. Afzal AR, Jeffery S,. One gene, two phenotypes: ROR2 mutations in autosomal recessive Robinow syndrome and autosomal dominant brachydactyly type B. Human Mutat 2003; 22: 1-11. (Pubitemid 36807767)
33. Billiard J, Way DS, Seestaller-Wehr LM, et al. The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. Mol Endocrinol 2005; 19: 90-101. (Pubitemid 40065961)
34. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002; 1: 279-88. (Pubitemid 41039152)
35. Dejmek J, Dejmek A, Safholm A, et al. Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res 2005; 65: 9142-6. (Pubitemid 41507974)
36. Jonsson M, Dejmek J, Bendahl PO, et al. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 2002; 62: 409-16. (Pubitemid 34106413)
37. Dejmek J, Leandersson K, Manjer J, et al. Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res 2005; 11 (2 Pt 1): 520-8. (Pubitemid 40116875)
38. Klemm F, Bleckmann A, Siam L, et al. beta-catenin-independent WNT signaling in basal-like breast cancer and brain metastasis. Carcinogenesis 2011; 32: 434-42.
39. Pukrop T, Klemm F, Hagemann T, et al. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc Natl Acad Sci U S A 2006; 103: 5454-9.
40. Grumolato L, Liu G, Mong P, et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev 2010; 24: 2517-30.
41. Kani S, Oishi I, Yamamoto H, et al. The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase Iepsilon. J Biol Chem 2004; 279: 50102-9. (Pubitemid 39577822)
42. Yamamoto H, Yoo SK, Nishita M, et al. Wnt5a modulates glycogen synthase kinase 3 to induce phosphorylation of receptor tyrosine kinase Ror2. Genes to Cells 2007; 12: 1215-23. (Pubitemid 350042419)
43. Nishita M, Itsukushima S, Nomachi A, et al. Ror2/frizzled complex mediates Wnt5a-induced AP-1 activation by regulating dishevelled polymerization. Mol Cell Biol 2010; 30: 3610-19.
44. Mikels A, Minami Y, Nusse R,. Ror2 receptor requires tyrosine kinase activity to mediate Wnt5A signaling. J Biol Chem 2009; 284: 30167-76.
45. Sato A, Yamamoto H, Sakane H, et al. Wnt5a regulates distinct signalling pathways by binding to Frizzled2. EMBO J 2010; 29: 41-54.
46. Ishitani T, Kishida S, Hyodo-Miura J, et al. The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol 2003; 23: 131-9. (Pubitemid 36008507)
47. DeChiara TM, Kimble RB, Poueymirou WT, et al. Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development. Nat Genet 2000; 24: 271-4. (Pubitemid 30132196)
48. Endo M, Doi R, Nishita M, et al. Ror family receptor tyrosine kinases regulate the maintenance of neural progenitor cells in the developing neocortex. J Cell Sci 2012; 125 (Pt 8): 2017-29.
49. Maeda K, Kobayashi Y, Udagawa N, et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 2012; 18: 405-U166.
50. Panelos J, Massi D,. Emerging role of Notch signaling in epidermal differentiation and skin cancer. Cancer Biol Ther 2009; 8: 1986-93.
51. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36: 417-22. (Pubitemid 38437267)
52. Wright TM, Brannon AR, Gordan JD, et al. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene 2009; 28: 2513-23.
53. Yamagata K, Li X, Ikegaki S, et al. Dissection of Wnt5a-Ror2 signaling leading to matrix metalloproteinase (MMP-13) expression. J Biol Chem 2012; 287: 1588-99.
54. Kobayashi M, Shibuya Y, Takeuchi J, et al. Ror2 expression in squamous cell carcinoma and epithelial dysplasia of the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107: 398-406.
55. Edris B, Espinosa I, Muhlenberg T, et al. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol 2012; 227: 223-33.
56. Nishita M, Yoo SK, Nomachi A, et al. Filopodia formation mediated by receptor tyrosine kinase Ror2 is required for Wnt5a-induced cell migration. J Cell Biol 2006; 175: 555-62. (Pubitemid 44790609)
57. Ren D, Minami Y, Nishita M,. Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition. Genes to Cells 2011; 16: 304-15.
58. Enomoto M, Hayakawa S, Itsukushima S, et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 2009; 28: 3197-208.
59. Yamamoto H, Oue N, Sato A, et al. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 2010; 29: 2036-46.
60. Geng M, Cao YC, Chen YJ, et al. Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis. World J Gastroenterol 2012; 18: 1328-38.
61. Lara E, Calvanese V, Huidobro C, et al. Epigenetic repression of ROR2 has a Wnt-mediated, pro-tumourigenic role in colon cancer. Mol Cancer 2010; 9: 170.
62. Yuan YA, Niu CC, Deng G, et al. The Wnt5a/Ror2 noncanonical signaling pathway inhibits canonical Wnt signaling in K562 cells. Int J Mol Med 2011; 27: 63-69.
63. Roman-Gomez J, Jimenez-Velasco A, Cordeu L, et al. WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. Eur J Cancer 2007; 43: 2736-46. (Pubitemid 350161849)
64. Nusse R, Varmus H,. Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J 2012; 31: 2670-84.
65. Kubo T, Kuroda Y, Shimizu H, et al. Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer. Carcinogenesis 2009; 30: 1857-64.